Co-Target(s) Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T73992 | Target Info | |||
Target Name | Beta-secretase (BACE) | ||||
Synonyms |
Transmembrane aspartic protease; Beta-site amyloid precursor protein cleaving enzyme; Beta-site AbetaPP-cleaving enzyme; BACE1
Click to Show/Hide
|
||||
Target Type | Clinical trial Target | ||||
Gene Name | NO-GeName | ||||
Biochemical Class | Peptidase | ||||
UniProt ID |
Co-Targets of This Target | Top | |||||
---|---|---|---|---|---|---|
Co-Target Name | Gamma-secretase (GS) | Clinical trial Target | ||||
UniProt ID | APH1A_HUMAN; APH1B_HUMAN; PEN2_HUMAN; NICA_HUMAN; PSN1_HUMAN | |||||
Gene Name | APH1A; APH1B; NCSTN; PSENEN; PSEN1 | |||||
Synonyms |
Presenilin-stabilization factor-like; PSFL; Aph-1beta
Click to Show/Hide
|
|||||
Representative Drug(s) | RG7129 | Drug Info | IC50 = 30 nM | [1] | ||
Co-Target Name | Albendazole monooxygenase (CYP3A4) | Clinical trial Target | ||||
UniProt ID | CP3A4_HUMAN | |||||
Gene Name | CYP3A4 | |||||
Synonyms |
Taurochenodeoxycholate 6-alpha-hydroxylase; Quinine 3-monooxygenase; P450-PCN1; Nifedipine oxidase; NF-25; HLp; Cytochrome P450-PCN1; Cytochrome P450 NF-25; Cytochrome P450 HLp; Cytochrome P450 3A4; Cytochrome P450 3A3; CYPIIIA4; CYPIIIA3; CYP3A3; Albendazole sulfoxidase; Albendazole monooxygenase (sulfoxide-forming); 1,8-cineole 2-exo-monooxygenase
Click to Show/Hide
|
|||||
Representative Drug(s) | PMID23981898C11d | Drug Info | IC50 = 100 nM | Click to Show More | [2] | |
2 | PMID23981898C11d | Drug Info | IC50 = 200 nM | [2] | ||
Co-Target Name | Cathepsin D (CTSD) | Clinical trial Target | ||||
UniProt ID | CATD_HUMAN | |||||
Gene Name | CTSD | |||||
Synonyms |
CPSD; CD
Click to Show/Hide
|
|||||
Representative Drug(s) | PMID23981898C11d | Drug Info | IC50 = 820 nM | [2] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead. Eur J Med Chem. 2018 Mar 25;148:436-52. | ||||
REF 2 | Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective beta-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid beta-peptides. Bioorg Med Chem Lett. 2013 Oct 1;23(19):5300-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.